Hirsutism and Baldness in Elderly Women

Definitions: hirsutism is excessive growth of terminal (coarse, pigmented) hair in a male pattern in a woman — upper lip, chin, chest, upper abdomen, back and thighs. It must be distinguished from hypertrichosis, which is generalised excess of vellus or terminal hair, is not androgen-dependent, and is usually drug-induced or familial.

Why both problems appear together after the menopause: ovarian follicles are depleted so oestrogen production falls sharply, while ovarian stromal and thecal androgen production and adrenal androgens are relatively preserved. The resulting rise in the androgen:oestrogen ratio produces facial hirsutism and scalp hair loss in the same woman — a classic examination point.

Common causes: idiopathic hirsutism; long-standing polycystic ovary syndrome; obesity and insulin resistance (adipose tissue is a major site of aromatisation and of altered SHBG); and drugs — glucocorticoids, danazol, testosterone and anabolic steroids cause true hirsutism, while minoxidil, ciclosporin, phenytoin and diazoxide cause hypertrichosis.

Sinister causes that must be excluded: androgen-secreting ovarian or adrenal tumour, ovarian hyperthecosis, Cushing's syndrome, non-classical congenital adrenal hyperplasia, acromegaly, hyperprolactinaemia and thyroid disease. New or rapidly progressive hirsutism with virilisation in a postmenopausal woman is a tumour until proved otherwise.

Virilisation red flags: onset over weeks to months, clitoromegaly, deepening of the voice, temporal balding, breast atrophy, increased muscle bulk, and biochemically a total testosterone above 150–200 ng/dL or DHEAS above 700 µg/dL.

Assessment of hirsutism: the modified Ferriman–Gallwey score — nine androgen-sensitive areas each scored 0 (no hair) to 4 (frankly virile). An abnormal score (conventionally ≥8, but ethnicity-adjusted — lower thresholds for East Asian and higher for Mediterranean and South Asian women) warrants androgen testing. Investigations: early-morning total and free testosterone, DHEAS, 17-hydroxyprogesterone, prolactin, TSH, and overnight dexamethasone suppression if Cushing's is suspected; then transvaginal ultrasound and adrenal CT if androgens are markedly raised.

Female pattern hair loss (FPHL): diffuse thinning over the crown with widening of the central parting and preservation of the frontal hairline (Ludwig pattern) — in contrast to the bitemporal recession of male-pattern loss. It affects up to two-thirds of postmenopausal women. Exclude telogen effluvium, iron deficiency, thyroid disease, and the scarring alopecias — particularly frontal fibrosing alopecia, characteristically a postmenopausal condition with eyebrow loss and a receded, pale hairline.

Investigations for hair loss: ferritin (aim above 40–60 ng/mL, not merely above the laboratory lower limit), TSH, vitamin D, complete blood count, and a careful drug review; clinically, the hair pull test and dermoscopy (trichoscopy) showing hair-shaft diameter diversity.

Treatment of hirsutism: Direct hair removal — shaving, plucking, threading, waxing and depilatories; definitive removal by electrolysis or laser/photoepilation (most effective for dark hair on light skin; multiple sessions needed). Topical eflornithine 13.9% cream slows facial hair growth (it inhibits ornithine decarboxylase) and is useful as an adjunct. Systemic antiandrogens for moderate to severe disease: spironolactone 50–100 mg/day — monitor potassium and renal function carefully in the elderly and avoid combining with ACE inhibitors or ARBs; alternatives are finasteride and cyproterone acetate. Flutamide should be avoided because of hepatotoxicity. Allow at least 6 months before judging response, because the hair growth cycle is slow. Contraception is not a concern in this age group, unlike in premenopausal women.

Treatment of female pattern hair loss: topical minoxidil 5% is the only FDA-approved option — expect results at 4–6 months, peak benefit at 6–12 months, and loss of benefit if stopped. Correct iron and thyroid deficiency first, since no topical agent compensates for an untreated nutritional or endocrine cause. Add an antiandrogen or 5-alpha reductase inhibitor for greater effect; procedural adjuncts include microneedling, platelet-rich plasma and low-level laser therapy. Both conditions cause substantial psychological distress and a perceived loss of femininity — address body image, mood and social withdrawal explicitly, as part of the geriatric assessment. Latest Updates & Current Practice (2023–Present) — 3 Points Low-dose oral minoxidil (0.625–2.5 mg/day) has become a mainstream option for female pattern hair loss. A 2025 JAAD meta-analysis and ambulatory blood-pressure monitoring studies found no clinically significant fall in blood pressure at these doses, with hypertrichosis the commonest side effect. This is directly relevant to older women, who often cannot tolerate or physically apply the topical form — roughly 40% of women in one Mayo Clinic series had abandoned topical minoxidil for local side effects or adherence difficulty. Antiandrogen therapy in FPHL (JAAD 2025 review): combination therapy consistently beats monotherapy. Oral bicalutamide 25 mg/day is emerging, although a randomised trial found no clear added benefit over oral minoxidil alone within 6 months. Importantly, the androgenic contribution to FPHL is now considered less certain than in men — most affected women have normal androgen levels, and androgen excess in women manifests as hirsutism rather than alopecia. Guidance on investigation: the Endocrine Society hirsutism guideline (2018, still current) and SOGC Guideline No. 444 (2023) advise against biochemical androgen testing in women with only mild localised unwanted hair and a normal hirsutism score, recommend pharmacological therapy plus hair removal for patient-important hirsutism, and advise strongly against flutamide. A 2024 JAMA Dermatology systematic review confirms the efficacy of laser and light-based therapies.